Background: Inflammatory bowel disease (IBD) mostly comprised of Crohn’s disease (CD) and ulcerative colitis (UC) is a condition arising from the combined effects of genetic, environmental, and immunological factors. IBD is associated with inflammation and altered cytokine profile. Objective: This study was aimed at assessing the association between T helper type 1 (Th1) cytokine polymorphisms (interferon gamma [IFN-γ] +874 A/T, interleukin-12 [IL-12] –1188 A/C, IL-2 –330 G/T, IL-2 +166 G/T) and susceptibility to and clinical features of IBD. Methods: The study population was composed of 75 IBD patients (40 CD patients and 35 UC patients) and 140 healthy controls. Genotyping was performed using polymerase chain reaction with sequence-specific primers. Results: The A allele of IFN-γ +874 polymorphism was overrepresented in the whole population of patients with IBD (OR 1.63; 95% CI 1.08–2.47; p = 0.020) and as well in the subpopulation of patients with CD (OR 2.14; 95% CI 1.26–3.63; p = 0.004), but not in UC. Multiple pairwise comparisons indicated that genotypes of single nucleotide polymorphisms (SNPs) within the IL-2 and IFN-γ genes are correlated with IBD, CD, and UC, while neither allele nor genotype frequency of th1 IL-12 –1188 polymorphism was associated with IBD, CD, or UC. Haplotype analysis also revealed that the presence of IL-2 –330/+166 TG haplotype versus the remaining haplotypes (GG, TT, and GT) is a protective factor against IBD (OR 0.62; p = 0.046). Conclusions: The present study reports (for the first time) significant associations between SNPs within the IFN-γ and IL-2 genes and IBD.

1.
Hanauer SB: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12: S3–S9.
2.
Saghazadeh A, Rezaei N: Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol 2016; 99: 272–285.
3.
Podolsky DK: Inflammatory bowel disease. N Engl J Med 1991; 325: 1008–1016.
4.
Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504–1517.
5.
Ng SC: Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol 2014; 28: 363–372.
6.
Fiocchi C: Inflammatory bowel disease: -etiology and pathogenesis. Gastroenterology 1998; 115: 182–205.
7.
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D’Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; The International IBDGC, Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119–124.
8.
de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achury J, Ji SG: Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 2017; 49: 256–261.
9.
Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015; 47: 979–986.
10.
Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427–434.
11.
Galli SJ, Borregaard N, Wynn TA: Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 2011; 12: 1035–1044.
12.
Zhu J, Paul WE: CD4 T cells: fates, functions, and faults. Blood 2008; 112: 1557.
13.
Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S: Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn’s disease. Am J Pathol 1997; 150: 823–832.
14.
Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, Corazza GR, Monteleone G, Di Sabatino A, MacDonald TT: Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. Gut 2009; 58: 1629–1636.
15.
Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65.
16.
Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann  R: Peripheral and intestinal regulatory CD4+CD25 high T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868–1878.
17.
Niessner M, Volk BA: Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995; 101: 428–435.
18.
Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261.
19.
Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz C: Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut 2004; 53: 1082–1089.
20.
López-Maderuelo D, Arnalich F, Serantes R, Gonzalez A, Codoceo R, Madero R, Vázquez JJ, Montiel C: Interferon-γ and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 167: 970–975.
21.
Amim LH, Pacheco AG, Fonseca-Costa J, Loredo CS, Rabahi MF, Melo MH, Ribeiro FC, Mello FC, Oliveira MM, Lapa e Silva JR, Ottenhoff TH, Kritski AL, Santos AR: Role of IFN-γ +874 T/A single nucleotide polymorphism in the tuberculosis outcome among Brazilians subjects. Mol Biol Rep 2008; 35: 563–566.
22.
Mahmoud AA, Sheneef A, Goda AM, Ismail MA, Abualfadl EM: Association of interferon-γ and its (+874 T/A) gene polymorphism with type 2 diabetes mellitus in rheumatoid arthritis patients. Egypt Rheumatol 2016; 38: 277–282.
23.
Cantor MJ, Nickerson P, Bernstein CN: The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol 2005; 100: 1134–1142.
24.
Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK, Avlund S, Olesen TB, Hoffmann HJ, Thomsen MK, Thomsen VO, Frydenberg M, Nexo BA, Sode J, Vogel U, Andersen V: Associations between functional polymorphisms in the NF[kappa]B signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J 2014; 14: 526–534.
25.
Glas J, Seiderer J, Wagner J, Olszak T, Fries C, Tillack C, Friedrich M, Beigel F, Stallhofer J, Steib C, Wetzke M, Goke B, Ochsenkuhn T, Diegelmann J, Czamara D, Brand S: Analysis of IL12B gene variants in inflammatory bowel disease. PLoS One 2012; 7:e34349.
26.
Marquez A, Mendoza JL, Taxonera C, Diaz-Rubio M, De La Concha EG, Urcelay E, Martinez A: IL23R and IL12B polymorphisms in Spanish IBD patients: no evidence of interaction. Inflammatory bowel diseases 2008; 14: 1192–1196.
27.
John S, Turner D, Donn R, Sinnott P, Worthington J, Ollier WER, Hutchinson IV, Hajeer AH: Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenet 1998; 25: 419–420.
28.
Queiroz DM, Oliveira AG, Saraiva IE, Rocha GA, Rocha AM, das Gracas Pimenta Sanna M, Guerra JB, Dani R, Ferrari Mde L, Castro LP: Immune response and gene polymorphism profiles in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2009; 15: 353–358.
29.
Barkhordari E, Rezaei N, Mahmoudi M, Larki P, Ahmadi-Ashtiani HR, Ansaripour B, Alighardashi M, Bashashati M, Amirzargar AA, Ebrahimi-Daryani N: T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. Inflammation 2010; 33: 281–286.
30.
Gomes P, du Boulay C, Smith CL, Holdstock G: Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92–95.
31.
Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn’s disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–444.
32.
Amirzargar AA, Naroueynejad M, Khosravi F, Dianat SS, Rezaei N, Mytilineos J, Nikbin B: Cytokine single nucleotide polymorphisms in Iranian populations. Eur Cytokine Net 2008; 19: 104–112.
33.
Abbasi F, Soltani S, Saghazadeh A, Soltaninejad E, Rezaei A, Zare Bidoki A, Bahrami T, Amirzargar AA, Rezaei N: PTPN22 single-nucleotide polymorphisms in iranian patients with type 1 diabetes mellitus. Immunol Invest 2017; 46: 409–418.
34.
Soltani S, Saghazadeh A, Movahedi M, Tavakol M, Sadr M, Farhadi E, Rezaei N: FLG single nucleotide polymorphisms in chronic idiopathic urticaria. Allergol Immunopathol 2016; 44: 341–345.
35.
Aflatounian M, Rezaei A, Sadr M, Saghazadeh A, Elhamian N, Sadeghi H, Motevasselian F, Farahmand F, Fallahi G, Motamed F: Association of PTPN22 Single nucleotide polymorphisms with celiac disease. Fetal Pediatr Pathol 2017: 1–8.
36.
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2004; 21: 263–265.
37.
Wang J, Shete S: Using both cases and controls for testing hardy-weinberg proportions in a genetic association study. Human Heredity 2010; 69: 212–218.
38.
Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-γ: an overview of signals, mechanisms and functions. J Leukocyte Biol 2004; 75: 163–189.
39.
Biolo G, Amoroso A, Savoldi S, Bosutti A, Martone M, Pirulli D, Bianco F, Ulivi S, Bertok S, Artero M, Barazzoni R, Zanetti M, Grassi G, Guarnieri G, Panzetta G: Association of interferon-gamma +874A polymorphism with reduced long-term inflammatory response in haemodialysis patients. Nephrol Dial Transpl 2006; 21: 1317–1322.
40.
Trinchieri G: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995; 13: 251–276.
41.
Alvarado-Navarro A, Montoya-Buelna M, Munoz-Valle JF, Lopez-Roa RI, Guillen-Vargas C, Fafutis-Morris M: The 3-UTR 1188 A/C polymorphism in the interleukin-12p40 gene (IL-12B) is associated with lepromatous leprosy in the west of Mexico. Immunol Lett 2008; 118: 148–151.
42.
Arababadi M, Pourfathollah A, Jafarzadeh A, Hassanshahi G, Daneshmandi S, Shamsizadeh A, Kennedy D: Non-association of IL-12 +1188 and IFN-γ +874 polymorphisms with cytokines serum level in occult HBV infected patients. Saudi J Gastroenterol 2011; 17: 30–35.
43.
Padron-Morales J, Sanz C, Davila I, Munoz-Bellido F, Lorente F, Isidoro-Garcia M: Polymorphisms of the IL12B, IL1B, and TNFA genes and susceptibility to asthma. J Invest Allergol Clin Immunol 2013; 23: 487–494.
44.
Thada S, Ponnana M, Sivangala R, Joshi L, Alasandagutti M, Ansari MS, Schumann RR, Valluri V, Gaddam S: Polymorphisms of IFN-gamma (+874A/T) and IL-12 (+1188A/C) in tuberculosis patients and their household contacts in Hyderabad, India. Human Immunol 2016; 77: 559–565.
45.
Dundar NO, Gencpinar P, Sallakci N, Duman O, Haspolat S, Anlar B, Yegin O: Interleukin-12 (–1188) A/C and interferon-γ (+874) A/T gene polymorphisms in subacute sclerosing panencephalitis patients. J Neuro Virol 2016; 22: 661–665.
46.
Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J, Bruce IN, Barton A: Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008; 58: 3705–3709.
47.
Shokrgozar MA, Sarial S, Amirzargar A, Shokri F, Rezaei N, Arjang Z, Radfar J, Yousefi-Behzadi M, Ali Sahraian M, Lotfi J: IL-2, IFN-gamma, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis. J Clin Immunol 2009; 29: 747–751.
48.
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Consortium NIG, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E; Belgian-French IBDC, Wellcome Trust Case Control C, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955–962.
49.
Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagace C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panes J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246–252.
50.
Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010; 42: 1118–1125.
51.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Ustekinumab Crohn’s Disease Study G: A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130–1141.
52.
Gaffen SL, Liu KD: Overview of interleukin-2 function, production and clinical applications. Cytokine 2004; 28: 109–123.
53.
Trajkov D, Mirkovska-Stojkovikj J, Arsov T, Petlichkovski A, Strezova A, Efinska-Mladenovska O, Sandevska E, Gogusev J, Spiroski M: Association of cytokine gene polymorphisms with bronchial asthma in Macedonians. Iran J Allergy Asthma Immunol 2008; 7: 143–156.
54.
Reichert S, Machulla HK, Klapproth J, Zimmermann U, Reichert Y, Glaser C, Schaller HG, Schulz S: Interleukin-2 –330 and 166 gene polymorphisms in relation to aggressive or chronic periodontitis and the presence of periodontopathic bacteria. J Period Res 2009; 44: 628–635.
55.
Harsini S, Ziaee V, Tahghighi F, Mahmoudi M, Rezaei A, Soltani S, Sadr M, -Moradinejad MH, Aghighi Y, Rezaei N: Association of interleukin-2 and interferon--gamma single nucleotide polymorphisms with Juvenile systemic lupus erythematosus. Allergol Immunopathol 2016; 44: 422–426.
56.
Maddah M, Harsini S, Rezaei A, Sadr M, Zoghi S, Moradinejad MH, Ziaee V, Rezaei N: Association of Interleukin-2, but not Interferon-Gamma, single nucleotide polymorphisms with juvenile idiopathic arthritis. Allergol Immunopathol 2016; 44: 303–306.
57.
Wei YS, Lan Y, Zhang L, Wang JC: Association of the interleukin-2 polymorphisms with interleukin-2 serum levels and risk of nasopharyngeal carcinoma. DNA Cell Biol 2010; 29: 363–368.
58.
Brynskov J, Tvede N, Andersen CB, Vilien M: Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992; 33: 55.
59.
Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP: Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn’s disease but not ulcerative colitis. Gastroenterology 1992; 102: 1620–1627.
60.
Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253–261.
61.
Movahedi M, Tavakol M, Rahmani F, Amirzargar AA, Bidoki AZ, Heidari K, Gharagozlou M, Aghamohammadi A, Nabavi M, Soltani S, Rezaei N: Single nucleotide polymorphisms of IL-2, but not IL-12 and IFN-gamma, are associated with increased susceptibility to chronic spontaneous urticaria. Allergol Immunopathol 2017; 45: 333–338.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.